Arrowhead Pharmaceuticals FY Conference Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - **Focus**: RNA interference (RNAi) technology with a broad pipeline of drug candidates, particularly in cardiometabolic diseases and central nervous system (CNS) disorders [2][3] Key Highlights - **Pipeline**: Approximately 21-22 drug candidates currently in clinical studies, with a strong emphasis on cardiometabolic conditions, including obesity [2] - **CNS Platform**: Introduction of a new CNS platform allowing for subcutaneous injections to address CNS disorders, with the first candidate ARO-MAPT targeting Alzheimer's disease [3][4] Upcoming Milestones - **Phase 3 Programs**: Expected readouts in Q3 2026 for SHASTA-3 and SHASTA-4, focusing on plozasiran, a triglyceride-lowering drug for patients with severe hypertriglyceridemia (SHTG) [3][4] - **CNS Data**: Anticipated data readout for ARO-MAPT in late Q3 or early Q4 2026, focusing on tau protein knockdown [5] - **Obesity Programs**: Additional data from ARO-INHBE and ARO-IL27 programs expected later in 2026, with a focus on adipose tissue targeting [6] Product Launch and Market Strategy - **Waylivra Launch**: Approved for familial chylomicronemia syndrome (FCS) with 100 prescriptions in the first 10 weeks, indicating a faster-than-expected launch [7][9] - **Pricing Strategy**: Priced at $60,000 per year, justified by the potential to reduce acute pancreatitis events in high-risk patients [17][19] - **Value Proposition**: Emphasizes the drug's ability to significantly lower triglyceride levels (around 80% reduction) compared to competitors [10][14] Competitive Landscape - **Differentiation**: Waylivra shows superior efficacy with no reported hypersensitivity or thrombocytopenia compared to Ionis' olezarsen, which has a higher non-responder rate [14][15] - **Market Positioning**: Aiming to establish a strong foothold in the high-risk population with a compelling clinical profile [19][20] Clinical Data Expectations - **SHASTA-3 and SHASTA-4**: Anticipated triglyceride reductions in the high 60s to low 70s percentage range, with a focus on translating these reductions into lower acute pancreatitis rates [22][23] - **Safety Monitoring**: Utilizing modified Atlanta criteria for characterizing acute pancreatitis events in clinical trials [26] Future Directions - **Dimer Development**: Exploring the combination of GalNAc siRNAs for mixed hyperlipidemia, targeting both LDL and triglycerides [46][47] - **Expansion into Other Markets**: Potential future studies in non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatotic liver disease (MASH) [40][46] Financial Position and Collaborations - **Current Financial Health**: Strong position with no immediate need for new partnerships; focus on existing collaborations and internal development [57][59] - **Future Collaborations**: Limited appetite for new partnerships in the near term, with a focus on maximizing current assets [59] Conclusion Arrowhead Pharmaceuticals is poised for significant developments in 2026, with a robust pipeline and strategic focus on cardiometabolic diseases and CNS disorders. The company is leveraging its RNAi technology to address unmet medical needs while maintaining a competitive edge in the market through innovative pricing and product differentiation.

Company Overview & Strategy - Esperion is evolving into a global cardiometabolic biotech, advancing the CLEAR Outcomes trial and pre-clinical pipeline assets [6] - The company restructured and financed in 2021 to reduce cost burn and strengthen the cash balance [9] - Esperion launched two approved drugs in Q2 2020 in the U S, with strong IP protection anticipated until mid-2031 [9] Market & Products - Nearly 80% of very high-risk patients in the U S did not meet guideline-recommended LDL-C goals [18] - 8.7 million patients in the U S don't reach their LDL-C goals despite taking a statin, while 9.6 million with high LDL-C are not on statins [18] - Up to 20% of people who could be treated with a statin experience statin intolerance [18] - NEXLETOL & NEXLIZET are safe & well-tolerated oral options for LDL-C lowering [30] Financial Performance & Outlook - Q1 2022 U S revenue was $13.4 million [35] - Esperion has >$1.2 billion in potential future ex-U S collaboration milestones from Daiichi Sankyo & Otsuka [67] - Esperion's Q1 2022 cash, cash equivalents, restricted cash & investment securities available-for-sale totaled $268.5 million [67] Clinical Development - The CLEAR Outcomes trial is approaching 100% MACE accumulation in 2H 2022, with top-line results anticipated in Q1 2023 [43] - Over 14,000 patients in 32 countries are fully enrolled in the CLEAR Outcomes trial [44]

Summary of Ventyx Biosciences (VTYX) Conference Call Company Overview - **Company**: Ventyx Biosciences (VTYX) - **Date**: June 5, 2025 - **Key Speakers**: Raju Mohan (CEO), Matt Moore (COO) Key Programs and Trials - Ventyx is focused on its pipeline, particularly in the field of inflammasomes, specifically NLRP3 [7][8] - Three Phase II readouts are anticipated: 1. **Parkinson's Disease Trial**: In early Parkinson's patients using CNS molecule VTX-3232, with results expected in June 2025 [8][9][10] 2. **Recurrent Pericarditis Trial**: An open-label trial modeled after Arcalist, with results expected in the second half of 2025 [13][15] 3. **Obesity and Cardiometabolic Risk Trial**: A placebo-blinded trial using VTX-3232, with results expected in the fall of 2025 [14][15] Financial Position - Ventyx is in a strong cash position with approximately $200 million available, allowing for continued execution of trials without immediate pressure to seek partnerships or sales [19][81][84] Strategic Partnerships - Sanofi has a right of first negotiation (ROFIN) for VTX-3232, which will be triggered after the cardiometabolic readout [21][25] - The interest from Sanofi is heightened due to their commitment to neurodegenerative diseases and previous successes in the field [26][27] Market Interest and Valuation - The stock is currently trading at a low valuation, around cash levels, attracting interest from various investors [20][21] - The upcoming data releases are expected to significantly impact investor sentiment and stock valuation [20][22] Data Expectations and Success Criteria - For the Parkinson's trial, success is defined by: - Safety of the treatment - Evidence of drug exposure in cerebrospinal fluid (CSF) - Biomarker modulation in CSF, particularly suppression of IL-1 beta and downstream effects [42][43][62][72] - The obesity trial is designed to detect weight loss and other metabolic markers, with a focus on safety and activity [113][125] Competitive Landscape - Roche is also conducting trials related to NLRP3 in Parkinson's, but has not released data, creating uncertainty in the competitive landscape [91][97] - Other companies are exploring similar pathways, indicating a growing interest in inflammasome inhibitors [98][108] Conclusion - Ventyx is positioned for significant developments in the coming months with multiple trials and potential strategic partnerships on the horizon. The focus remains on executing trials effectively while maintaining a strong financial position to support long-term growth and value creation for shareholders [84][90][135]